Heron Therapeutics
HRTX
175 hedge funds and large institutions have $289M invested in Heron Therapeutics in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 54 increasing their positions, 58 reducing their positions, and 32 closing their positions.
2,008% more call options, than puts
Call options by funds: $2.61M | Put options by funds: $124K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 58
5% less funds holding
Funds holding: 185 → 175 (-10)
21.41% less ownership
Funds ownership: 118.8% → 97.4% (-21%)
25% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 32
44% less capital invested
Capital invested by funds: $514M → $289M (-$225M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$29.7M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$8.05M |
| 3 |
Millennium Management
New York
|
+$5.88M |
| 4 |
CC
Clearline Capital
New York
|
+$3.3M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$20.1M |
| 2 |
SCM
Suvretta Capital Management
New York
|
-$11.8M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$9.94M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$6.61M |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$6.57M |
HRTX Hedge Fund Activity: Q4 2022 in Review
175 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2022, worth a combined $289M — down 44% from $514M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of HRTX and 24 opened new positions — a net loss of 8 holders — while 58 trimmed existing stakes and 54 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $29.7M. The largest seller was State Street, cutting an estimated $20.1M.
- 175 institutional investors held Heron Therapeutics (HRTX) as of Q4 2022, down from 185 in Q3 2022.
- Funds reported $289M of Heron Therapeutics stock for Q4 2022, down 44% quarter-over-quarter.
- 24 funds opened new Heron Therapeutics positions in Q4 2022 and 32 closed out, a net change of -8 holders.
- The largest Heron Therapeutics buyer in Q4 2022 was Rubric Capital Management (New York), an estimated $29.7M added.
- The largest Heron Therapeutics seller in Q4 2022 was State Street, an estimated $20.1M sold.
Based on aggregated 13F filings for Q4 2022.